abs288.txt	importance		although	clonal	hematopoiesis	(ch)	is	well	described	in	aging	healthypopulations		few	studies	have	addressed	the	practical	clinical	implications	ofthese	alterations	in	solid-tumor	sequencing	objective		to	identify	and	quantify	ch-related	mutations	in	patients	with	solidtumors	using	matched	tumor-blood	sequencing		and	to	establish	the	proportion	thatwould	be	misattributed	to	the	tumor	based	on	tumor-only	sequencing	(unmatchedanalysis)	design		setting		and	participants		retrospective	analysis	of	samples	from	17	469patients	with	solid	cancers	who	underwent	prospective	clinical	sequencing	of	dnaisolated	from	tumor	tissue	and	matched	peripheral	blood	using	the	msk-impactassay	between	january	2014	and	august	2017	main	outcomes	and	measures		we	identified	the	presence	of	ch-related	mutations	ineach	patient's	blood	leukocytes	and	quantified	the	fraction	of	dna	moleculesharboring	the	mutation	in	the	corresponding	matched	tumor	sample	results		the	mean	age	of	the	17	469	patients	with	cancer	at	sample	collection	was59	2	years	(range		0	3-98	9	years)		53	6%	were	female		we	identified	7608ch-associated	mutations	in	the	blood	of	4628	(26	5%)	patients		a	total	of	1075(14	1%)	ch-associated	mutations	were	also	detectable	in	the	matched	tumor	aboveestablished	thresholds	for	calling	somatic	mutations		overall		912	(5	2%)patients	would	have	had	at	least	1	ch-associated	mutation	erroneously	called	astumor	derived	in	the	absence	of	matched	blood	sequencing		a	total	of	1061	(98	7%)of	these	mutations	were	absent	from	population	scale	databases	of	germlinepolymorphisms	and	therefore	would	have	been	challenging	to	filter	informatically	annotating	variants	with	oncokb	classified	534	(49	7%)	as	oncogenic	or	likelyoncogenic	conclusions	and	relevance		this	study	demonstrates	how	ch-derived	mutations	couldlead	to	erroneous	reporting	and	treatment	recommendations	when	tumor-onlysequencing	is	used	
